Sanofi (SAN) AI Stock Analysis

• Market Cap: €95.97B
• Dividend Yield: 4.77%
• Average Volume (3M): 1.95M
• Price to Earnings (P/E): 12.9
• Beta (1Y): 0.87
• Revenue Growth: -9.82%
• EPS Growth: 119.10%
• Country: FR
• Employees: 82,878
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - General
• EPS (TTM): 1.53
• Shares Outstanding: 1,219,502,200
• 10 Day Avg. Volume: 1,590,247
• 30 Day Avg. Volume: 1,950,864
• PEG Ratio: 0.28
• Price to Book (P/B): 1.41
• Price to Sales (P/S): 2.31
• P/FCF Ratio: 11.23
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: €96.97
• Price Target Upside: 21.42% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 13
• EPS Forecast (FY): 8.43
• Revenue Forecast (FY): €48.10B

• Rating: 66 Neutral
• Price Target: €86.00 ▲(7.69% Upside)
• Action: Downgraded Date: 02/23/26
• Date: Action: Downgraded 02/23/26

The score is driven primarily by solid profitability and a conservatively positioned balance sheet, tempered by a 2025 revenue decline and a sharp drop in free cash flow. Technical signals are mildly weak (negative MACD and below key moving averages), while valuation is supported by a reasonable P/E and a strong dividend yield.

Positive Factors

High gross margins

Sustained gross margins near 68–71% indicate durable product-level profitability and pricing power across the portfolio. High gross margins provide structural capacity to fund R&D, absorb SG&A and commercialization costs, and support long-term operating leverage even if top-line growth softens.

Conservative balance sheet

A conservative leverage profile for a large pharma (debt-to-equity ~0.23–0.38) and a large equity base give Sanofi durable financial flexibility. This positioning supports continued M&A, dividend policy and R&D investment without forcing distressed funding choices during cyclical downturns.

Expanded adult vaccines portfolio

The Dynavax acquisition adds a marketed, differentiated adult hepatitis B vaccine (HEPLISAV-B) and a shingles candidate, strengthening Sanofi Pasteur's adult immunization franchise. This is a structural expansion of commercial and pipeline assets that can diversify revenue and leverage global manufacturing and sales scale.

Negative Factors

2025 revenue decline

A 7% revenue contraction in 2025 marks a material weakening in top-line momentum after prior modest growth. Persistent or recurring declines would strain growth prospects, increase reliance on acquisitions or new launches, and make long-term revenue recovery dependent on successful pipeline commercialization.

Sharp free cash flow drop

A ~25% drop in free cash flow signals weakening cash conversion and higher cash uses or working-capital pressure. Reduced FCF constrains durable options to fund R&D, pay dividends, or pursue M&A without increasing leverage, and raises execution sensitivity to operational or market setbacks.

CEO transition and execution risk

A near-term CEO replacement and interim leadership create structural execution risk around strategy, integration of recent acquisitions and pipeline prioritization. Leadership changes can alter R&D focus, commercial strategy and organizational continuity, potentially delaying value realization from initiatives.

Sanofi Business Overview & Revenue Model

Company Description

Sanofi, together with its subsidiaries, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through three segments: Pharmaceuticals, Vaccines, and Consumer Healthcare. The company provides specialty care products, including human monoclonal antibodies; products for multiple sclerosis, neurology, other inflammatory diseases, immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes; and cardiovascular and established prescription products. It also supplies poliomyelitis, pertussis, and hib pediatric vaccines; and influenza, adult booster, meningitis, and travel and endemic vaccines. In addition, the company offers allergy, cough and cold, pain, liver care, physical and mental wellness, probiotics, digestive, and nutritional products; and other products, such as daily body lotions, anti-itch products, moisturizing and soothing lotions, and body and foot creams, as well as powders for eczema. Further, it has various pharmaceutical products and vaccines in development stage. Sanofi has collaboration agreement with GlaxoSmithKline to develop a recombinant Covid-19 vaccine; and a research collaboration with Stanford University School of Medicine to advance the understanding of immunology and inflammation through open scientific exchange. It also has a collaboration and license option agreement with Prellis Biologics, Inc. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was founded in 1973 and is headquartered in Paris, France.

How the Company Makes Money

Sanofi generates revenue primarily through the sale of prescription pharmaceuticals, vaccines, and consumer healthcare products. The company's revenue model is driven by its proprietary drug portfolio, which includes well-known medications and therapies that cater to chronic and acute health conditions. Key revenue streams include sales from diabetes care products, oncology treatments, and vaccines, particularly those targeting influenza and other infectious diseases. Sanofi also engages in strategic partnerships and collaborations with other pharmaceutical companies, academic institutions, and research organizations to enhance its R&D capabilities and expand its product offerings. Additionally, the company benefits from licensing agreements and royalties from its innovative therapies, contributing significantly to its overall earnings.

Sanofi Financial Statement Overview

Summary

Financials are solid overall: strong gross margins (~68–71%) and moderate leverage (debt-to-equity ~0.31 in 2025). Offsetting factors are softer growth (2025 revenue -7.0%) and weakening cash-flow momentum (2025 free cash flow -25.3%) despite improved net margin (~17.9% in 2025 vs ~12.6% in 2024).

Income Statement

Sanofi shows strong underlying profitability with consistently high gross margins (~68–71%) and solid operating profitability, but growth has softened. Revenue rose modestly from 2021–2024 before declining in 2025 (-7.0%). Profitability is volatile: net margin fell from a very strong 2020 level and rebounded in 2025 (net margin ~17.9% vs ~12.6% in 2024), suggesting improving earnings power, but with year-to-year swings.

Balance Sheet

The balance sheet looks conservatively positioned for a large pharma company, with moderate leverage (debt-to-equity roughly ~0.23–0.38 across the period; ~0.31 in 2025) and a large equity base. Returns on equity are generally healthy (mostly ~7–11%, with 2025 ~10.9%), though not consistently expanding. A watch item is that leverage ticked up in 2025 versus 2024, even as revenue contracted.

Cash Flow

Cash generation is solid with consistently positive free cash flow, and free cash flow generally tracks earnings well (free cash flow running at ~65–84% of net income). However, cash flow momentum weakened recently: free cash flow declined in 2024 and fell sharply again in 2025 (free cash flow growth -25.3%), indicating higher cash uses or weaker cash conversion versus prior years despite improved net income.

Breakdown	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	43.63B	44.29B	41.11B	40.30B	39.17B
Gross Profit	30.58B	31.09B	28.49B	28.43B	26.92B
EBITDA	6.74B	11.66B	11.08B	13.09B	11.25B
Net Income	7.81B	5.56B	5.40B	8.37B	6.22B
Balance Sheet
Total Assets	126.81B	132.80B	126.46B	126.72B	120.24B
Cash, Cash Equivalents and Short-Term Investments	7.66B	7.93B	8.98B	13.40B	11.15B
Total Debt	21.80B	17.91B	18.42B	21.21B	22.41B
Total Liabilities	55.10B	54.94B	52.11B	51.57B	51.21B
Stockholders Equity	71.38B	77.51B	74.04B	74.78B	68.68B
Cash Flow
Free Cash Flow	8.99B	5.89B	8.64B	8.32B	8.48B
Operating Cash Flow	10.75B	9.08B	10.26B	10.53B	10.52B
Investing Cash Flow	-2.45B	-4.41B	-6.20B	-2.08B	-7.30B
Financing Cash Flow	-8.21B	-5.76B	-8.05B	-5.82B	-7.06B

Sanofi Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 79.86
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For FR:SAN, the sentiment is Negative. The current price of 79.86 is below the 20-day moving average (MA) of 80.17, below the 50-day MA of 80.65, and below the 200-day MA of 83.55, indicating a bearish trend. The MACD of 0.08 indicates Negative momentum. The RSI at 48.01 is Neutral, neither overbought nor oversold. The STOCH value of 73.89 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for FR:SAN.

Sanofi Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
VIRP	75 Outperform	€2.93B	8.13	12.92%	0.41%	6.97%	-5.59%
BIM	68 Neutral	€11.67B	32.73	9.69%	0.82%	8.28%	-8.08%
IPN	67 Neutral	€13.30B	22.37	10.82%	1.17%	9.57%	-34.30%
SAN	66 Neutral	€95.97B	12.92	8.39%	4.77%	-9.82%	119.10%
ERF	64 Neutral	€12.04B	23.65	11.27%	0.97%	6.25%	18.93%
DIM	52 Neutral	€17.01B	76.93	6.65%	0.31%	7.72%	53.84%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%